Gadolinium-Based Contrast Agents Associated with Nephrogenic Systemic Fibrosis
Not all gadolinium-based contrast agents have been equally implicated in nephrogenic systemic fibrosis (NSF)—the three linear agents gadodiamide (Omniscan), gadoversetamide (OptiMARK), and gadopentetate dimeglumine (Magnevist) account for the overwhelming majority of cases, while gadoteridol (ProHance) has only a single reported unconfounded case. 1
Risk Stratification by Agent
The evidence clearly stratifies gadolinium agents by NSF risk based on their molecular structure and stability:
High-Risk Linear Agents (Group I)
- Gadodiamide (Omniscan): Largest number of reported NSF cases 2, 3, 4
- Gadoversetamide (OptiMARK): Multiple confirmed cases 5, 3, 4
- Gadopentetate dimeglumine (Magnevist): Several documented cases 3, 6
These three linear nonionic and ionic agents are markedly less stable both in vitro and in vivo, with higher propensity to release free gadolinium through dechelation 1. The EMA Pharmacovigilance and Risk Assessment Committee recommended suspension of marketing authorization for these agents in 2017 specifically due to convincing evidence of gadolinium deposition and NSF risk 1.
Low-Risk Macrocyclic Agents (Group II)
- Gadoteridol (ProHance): Only one single unconfounded case reported in the literature 2
- Other macrocyclic agents (gadobutrol, gadoterate meglumine): Zero unconfounded cases in 4,931 stage 4-5 CKD patients (upper bound 95% CI: 0.07%) 7, 8
The macrocyclic structure provides superior thermodynamic and kinetic stability, with pre-organized rigid rings that strongly cage the gadolinium ion, preventing dechelation 1, 4.
Clinical Implications
The answer to your question is technically option (a), (b), and (c)—but NOT option (e). Gadoteridol (ProHance) has been associated with at least one case, but the risk profile is dramatically different from the linear agents. The FDA drug label for ProHance acknowledges NSF risk exists but emphasizes the distinction between agent classes 9.
Key Distinctions:
- Linear agents (Omniscan, OptiMARK, Magnevist): Hundreds of cases, now contraindicated in severe renal dysfunction 1, 10
- Macrocyclic agents (ProHance): Essentially negligible risk with proper screening 7, 8
Current Practice Recommendations:
For patients with eGFR <30 mL/min/1.73 m² or on dialysis:
- Absolutely contraindicated: Gadopentetate dimeglumine, gadodiamide, gadoversetamide 10
- May be used with informed consent: Macrocyclic agents including gadoteridol, with risk cited as "exceedingly low (much less than 1%)" 10
- Risk estimate upper bound: 0.07% for all Group II agents combined 7, 8
The most recent 2021 ACR/NKF consensus guidelines recommend Group II (macrocyclic) agents when GBCA is necessary in high-risk patients, with the understanding that while NSF risk is not zero, it approaches zero with modern macrocyclic agents 7.